Replies to post #44587 on Relief Therapeutics Holding AG (RLFTF)

[theswordman]

As part of the FDA's Coronavirus Treatment Acceleration Program, Relief Therapeutics, a Swiss company, is examining the effectiveness of Aviptadil, a patented synthetic
version of a human vasoactive intestinal polypeptide (VIP), for
COVID-19-related ARDS at New York University Langone (NYU Langone Health)
(CTAP).